CD14 and Huntington disease: Strikingly, the frequency of intermediate CD16+CD14+ and non-classical CD14−CD16+ monocytes remained extremely low throughout the follow-up, with a nadir at day 15 (0.4 and 0.02% versus 4.4% [2.9–5.8] and 4% [3.3–5.1] for HD, respectively) (Fig. 2i).